Allogeneic transplantation of haematopoietic progenitors for myelodysplastic syndromes and myeloproliferative disorders.
Since children with myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD) have a poor prognosis and conventional chemotherapy did not prove to be effective in eradicating them, paediatric patients affected by these diseases and with an HLA-histocompatible donor are to be considered elective candidates for allogeneic transplantation of haematopoietic stem cells (HSC). For those patients with a compatible sibling relapse remains the most important problem, whereas in children transplanted from alternative donors graft rejection and transplant-related mortality significantly contribute to treatment failure. A detailed analysis on the different patient, disease and treatment factors correlated with transplant outcome in childhood MDS and MPD is discussed.
Locatelli
F
F
Department of Pediatrics, University of Pavia, IRCCS Policlinico San Matteo, Italy.
Giorgiani
G
G
Comoli
P
P
D002648:Child; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D014184:Transplantation, Homologous